|
| |
OSI PharmaceuticalsOSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity.
We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and strive to turn pioneering science into breakthrough therapies for patients suffering from life-threatening diseases.
Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms.
Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity. (OSI) Prosidion has an emerging diabetes and obesity clinical pipeline with several innovative drug candidates that have progressed into clinical development.
OSI has a dedicated team of approximately 500 research and development, regulatory, sales, marketing, commercial, and business professionals. We are headquartered in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom.
Our Flagship Product
Tarceva (erlotinib) is a small molecule human epidermal growth factor type 1/epidermal growth factor receptor (HER1/EGFR) inhibitor which is currently marketed for the treatment of non-small cell lung cancer and pancreatic cancer.
Products and Pipeline
A key to our long-term success resides in our ability to continue to fund our deep and innovative pipeline, both to enhance the Tarceva franchise and seed high-quality research programs in oncology, diabetes and obesity.
| Contact Details: |
| 41 Pinelawn Road |
| Melville, |
| NY |
| 11747 |
| United States of America |
| Tel: | (631) 962-2000 |
| Fax: | (631) 752-3880 |
| Email: | investor_info@osip.com |
| WWW: | www.osip.com/
|
|
Loading...
|
Recent Publications by OSI Pharmaceuticals: |  |
High-Throughput Screening for mTORC1/mTORC2 Kinase Inhibitors Using a Chemiluminescence-Based ELISA Assay.
A high-throughput chemiluminescence and ELISA-based biochemical assay to... | 10th November, 2009
| Department of Cancer Biology, OSI Pharmaceuticals Inc., Farmingdale, New
| Assay Drug Dev Technol. 2009 Oct;7(5):471-478.
DOI Direct Link |
Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.
It would be helpful to have factors that could identify patients who will,... | 30th May, 2009
| Biostatistics and Data Management, OSI Pharmaceuticals, Inc., 2860
| Mol Oncol. 2008 Apr;1(4):406-12. Epub 2007 Dec 8.
DOI Direct Link |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
NSCLC cells with a mesenchymal phenotype have shown a marked reduction in... | 14th January, 2009
| Department of Translational Research, OSI Pharmaceuticals Inc., 1
| Clin Exp Metastasis. 2008;25(8):843-54. Epub 2008 Aug 12.
DOI Direct Link |
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I... | 8th November, 2008
| Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale,
| Cancer Res. 2008 Oct 15;68(20):8322-32.
DOI Direct Link |
Cytochrome P450 oxidation of the thiophene-containing anticancer drug 3-[(quinolin-4-ylmethyl)-amino]-thiophene-2-carboxylic acid (4-trifluoromethoxy-phenyl)-amide to an electrophilic intermediate.
Compounds that are enzymatically transformed to reactive intermediates are... | 10th October, 2008
| Drug Metabolism and Pharmacokinetics, OSI Pharmaceuticals, Boulder,
| Chem Res Toxicol. 2008 Aug;21(8):1570-7. Epub 2008 Aug 2.
DOI Direct Link |
→View more OSI Pharmaceuticals research publications. |
Press Releases on OSI Pharmaceuticals:
|
 |
| NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director |
24th November, 2009 |
NeurogesX, Inc. |
SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today
|
| Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals |
20th October, 2009 |
Simcere Pharmaceutical Group |
NANJING, China, Oct. 20 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group
(NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company
specializing in development
|
| Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists |
16th October, 2009 |
Reportlinker |
-- additional comments with a hyperlink leading to the source of
information.
Index
-- 2008 Sales of VEGF/R Antagonists
-- VEGF-R Agonists
-- Cardiovascular
|
| Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors |
16th October, 2009 |
Reportlinker |
-- additional comments with a hyperlink leading to the source of
information.
Index
-- Selective PI3K Inhibitors in Oncology Indications
-- Selective PI3K Inhibitors in
|
| New Report Just Published: World Prostate Cancer Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Prostate Cancer Therapeutics Market
http://www.reportlinker.com/p0119471/World
|
BioNews Results for OSI Pharmaceuticals:  | |
| Updates for OSI Pharmaceuticals (NASDAQ:OSIP), Perrigo (Nasdaq:PRGO), Sensient (NYSE:SXT) |
California Chronicle: Nov 21 2009 8:29PM Matching: osi pharmaceuticals
|
| BiomedReports: News and FDA Updates for OSI Pharmaceuticals (NASDAQ:OSIP), Perrigo (Nasdaq:PRGO), Sensient (NY |
Quote.com Japan: Nov 21 2009 11:46AM Matching: osi pharmaceuticals
|
| Updates for OSI Pharmaceuticals (NASDAQ:OSIP), Perrigo (Nasdaq:PRGO), Sensient (NYSE:SXT) |
Los Angeles Chronicle: Nov 21 2009 4:45AM Matching: osi pharmaceuticals
|
| Updates for OSI Pharmaceuticals (NASDAQ:OSIP), Perrigo (Nasdaq:PRGO), Sensient (NYSE:SXT) |
American Chronicle: Nov 21 2009 1:14AM Matching: osi pharmaceuticals
|
| BiomedReports: News and FDA Updates for OSI Pharmaceuticals (NASDAQ:OSIP), Perrigo (Nasdaq:PRGO), Sensient (NYSE:SXT) |
Individual.com: Nov 21 2009 2:43AM Matching: osi pharmaceuticals
|
| Promote your company here: BioNewsCast - Press Release Distribution | →View more OSI Pharmaceuticals news. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 11 individuals from OSI Pharmaceuticals using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 499 times since April 2007, the link to the organisation's website has been followed 90 times Recent Search Terms used to find this page: osi pharmaceuticals translational medicine | working at osi pharmaceuticals in nj | pharmacokinetics market research report | . Search for more companies in Melville, Search for more companies in NY This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for OSI Pharmaceuticals |
